Introduction
============

The endocannabinoid system (ECS) is involved in many physiological processes including metabolism, inflammation, pain, and neurotransmission ([@B21]; [@B57]). It consists of endogenous cannabinoids (EC), cannabinoid receptors (CBR), and EC metabolizing enzymes ([@B21]; [@B62]). Two major CBRs are identified: CBR type 1 (CB~1~R) and CBR type 2 (CB~2~R; [@B31]). CB~1~R are mainly expressed in the central nervous system (CNS) and a variety of non-neural peripheral tissues, including the vasculature and gut ([@B63]). CB~2~R are primarily expressed on immune cells but are also identified in selected CNS areas and some peripheral tissues ([@B40]). Recently another G protein-coupled receptor, GPR55, has garnered much attention due to its activation by EC and its impact on the immune system ([@B61]; [@B83]). Increasing evidence shows that enhanced EC levels occur during systemic inflammation, such as in sepsis or following a CNS injury. Manipulation of the ECS may have therapeutic effects in inflammatory disorders. In this review, we will focus on modulation of CB~2~ and GPR55 receptors on immune response in two inflammatory disorders, sepsis, and CNS injury. Both sepsis and CNS injury cause the immune system to go through rather rapid and dramatic changes from pro- to anti-inflammatory phases, which may end up costing patients their life. We suggest that the common mechanism for modulating and ultimately controlling the response of the immune system can be achieved through delicate interplay between the endocannabinoid, central nervous and immune systems.

ECS in Sepsis
=============

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection ([@B77]). An initial infection with the ensuing systemic inflammatory response becomes amplified, resulting in excessive release of both pro- and anti-inflammatory mediators, causing multi-organ dysfunction, failure, and death ([@B41]; [@B77]). Recently, the ECS has emerged as a potential therapeutic target in sepsis treatment due to its immune modulatory functions. The effect of modulation of CB~1~R, CB~2~R, and GPR55 in sepsis-induced systemic inflammation will be described below.

CB~1~R
------

Cannabinoid receptors type 1 are mainly pre-synaptic receptors in axon terminals and their activation causes post-synaptic inhibition by preventing neurotransmitter release ([@B17]; [@B42]). Manipulating the activity of CB~1~R at critical periods may play a therapeutic role in sepsis. Studies have suggested that pre-synaptic CB~1~R activation on autonomic nerves and vascular walls exacerbates the hypotension associated with septic shock through neurogenic mechanisms ([@B25]). However, studies using CB~1~R knockout mice subjected to endotoxemia showed acute hypotension indicating that other mechanisms are also responsible for hypotension during systemic inflammatory conditions ([@B8]). In a lipopolysaccharide (LPS) induced experimental sepsis model, we demonstrated that inhibition of CB~1~R by its antagonist, AM281, significantly reduced leukocyte activation and improved intestinal microcirculation ([@B38]) and iris microcirculation ([@B37]; [@B2]). However, the exact mechanisms of CB~1~R action in sepsis and septic shock are not yet completely understood and further studies are still required.

CB~2~R
------

Cannabinoid receptors type 2 are primarily expressed on immune cells and represent an ideal target for immune modulation ([@B40]). CB~2~R are G~i~-protein coupled receptors and signal primarily through regulating cAMP levels depending on the duration of activation of the receptor ([@B65]; [@B12]; [@B7]). CB~2~R also signal through the mitogen-activated protein kinase (MAPK) pathway by regulating the three major kinases: the extracellular signal-regulated protein kinases (ERK), p. 38, and c-Jun NH2-terminal kinases ([@B7]). Both of these major signaling pathways play important roles in CB~2~R-mediated immune modulating functions including effects on leukocyte activation, migration, proliferation, apoptosis, and cytokine production ([@B7]). In general, CB~2~R activation has shown an immune suppressive action, which can be exploited for therapeutic benefit in inflammatory diseases such as sepsis.

A variety of *in vitro* studies have shown contradictory results in terms of modulation of the immune response, mainly due to the use of non-selective cannabinoids ([@B53]). Some studies have shown that cannabinoids enhanced leukocyte proliferation in a dose dependent manner ([@B22]; [@B15]), while other studies have shown inhibitory effects on leukocyte proliferation through the activation of the CB~2~R ([@B47]; [@B7]). This inhibition maybe mediated by CB~2~R-dependent promotion of apoptosis in dendritic cells, splenocytes, and thymocytes, with some diminished activity when CB~2~R antagonists are used ([@B7]). Additional evidence also supports the role of CB~2~R in the promotion of apoptosis. For example, administration of the CB~2~R agonist, JWH-015, induced apoptosis in thymocytes and diminished the proliferative potential of T cells and B cells ([@B46]). Administration of the CB~2~R antagonist, AM630, showed a reversal of the induction of T cell apoptosis by JWH-133 (another CB~2~R agonist), strongly implicating a CB~2~R dependent mechanism ([@B78]). This evidence suggests that activation of CB~2~R may promote immune resolution by inducing apoptosis of immune cells, therefore minimizing excessive damage of the pro-inflammatory cascade that occurs early on in sepsis.

Using an experimental sepsis model, we demonstrated that activation of CB~2~R by the selective CB~2~R agonist, HU308, significantly reduced leukocyte adhesion in the microvasculature ([@B44]). Administration of EC degradation enzyme inhibitors, such as URB597 and JZL184, also decreased leukocyte activation in endotoxemic animals ([@B67]). However, reduced leukocyte activation by JZL184 is still present in endotoxemic CB~2~R knockout mice, suggesting that other mechanisms are also involved in the ECS-mediated immune regulation in sepsis.

Cytokine production by immune cells plays a critical role in the inflammatory response and can be modulated through CB~2~R. Multiple pro-inflammatory cytokines, such as TNF-α, interleukin (IL)-1β, and IL-6, are released in the early stages of the septic cascade. However, activation of the CB~2~R by its agonist HU308 reduced plasma levels of pro-inflammatory cytokines in endotoxemic rats ([@B44]). Administration of the EC, anandamide, decreased the levels of the proinflammatory cytokines IL-12 and IL-23 *in vitro* in activated microglial cells ([@B20]). In addition, T cell activation and release of IL-2 were inhibited by administration of the CB~2~R agonist, JWH-015, and this effect was eliminated by administration of the CB~2~R antagonist, AM630 ([@B12]). It was also demonstrated that activation of CB~2~R by HU308 enhanced the release of IL-10, a prominent anti-inflammatory cytokine, suggesting an immunosuppressive effect of CB~2~R ([@B40]).

GPR55
-----

GPR55 was initially described as a novel cannabinoid receptor or putative "CB~3~" receptor due to its high affinity to cannabinoid ligands such as Δ9-THC, 2-AG, anandamide, and rimonabant, independent of the presence of CB~1~R and CB~2~R ([@B68]; [@B9]; [@B61]; [@B66]). However, the limited sequence similarity between GPR55 and CBR does not support this concept ([@B4]). Unlike the classical CB~1~R and CB~2~R signaling pathway, GPR55 is coupled to Gα12 and Gα13 proteins, signaling through ras homolog gene family member A, Rho-associated protein kinase and phospholipase C pathway activation. Increased intracellular Ca^2+^ is followed to activate rhoA, Rac, and cdc42, thereby phosphorylating ERK, resulting in modulation of leukocyte chemotaxis, proliferation, and cytokine production ([@B66]; [@B27]).

GPR55 is widely expressed in the CNS, immune system, and peripheral tissues and is involved in many physiological and pathophysiological processes ([@B66]; [@B28]). In the immune system, GPR55 is highly expressed in the spleen and leukocytes, and its role in the modulation of innate and adaptive immune responses suggests a potential therapeutic effect for sepsis ([@B80]; [@B45]; [@B70]; [@B79]). GPR55 acts as an essential regulator in innate immunity via stimulatory effects in neutrophils, mast cells, monocytes, and natural killer (NK) cells ([@B5]; [@B14]; [@B69]; [@B18]). GPR55 on NK cells and monocytes increase pro-inflammatory cytokines, cell cytotoxicity, and decrease monocyte-mediated endocytosis upon activation by LPS ([@B18]). GPR55 expression was increased in the GI tract during sepsis ([@B45]) and GPR55 knockout mice showed least severe intestinal inflammation in comparison to CB~1~R or CB~2~R knockout mice in experimental colitis ([@B70]). In studies using adjuvant-induced inflammation, inflammatory mechanical hyperalgesia by Freund's complete adjuvant was absent in GPR55 knockout mice with increased levels of IL-4, IL-10, and IFN-γ ([@B80]). Importantly, GPR55 antagonist, CID16020046, diminished inflammation in experimental colitis by reducing the levels of pro-inflammatory cytokines, TNF-α, IL-1β, IL-6, and impairing leukocyte activation and migration ([@B79]). In our laboratory, we demonstrated that GPR55 antagonists, CID16020046, and O-1918, reduced LPS-induced leukocyte-endothelial interactions in experimental models of sepsis in mice ([@B84]).

GPR55 pharmacology with regards to ligand affinity and activity has been controversial in the current literature due to ligand- and concentration-specific biased signaling ([@B29]; [@B85]). GPR55 can form heteromers with CB~1~R or CB~2~R to elicit different pathways via ligand- and concentration-specific crosstalk ([@B5], [@B6]; [@B36]; [@B50]). Heteromers of CB~1~R and GPR55 are reported in CNS ([@B50]) and Human Embryonic Kidney cell lines ([@B36]). CB~1~R inhibits GPR55 signaling when they are co-expressed on a cell ([@B36]). Cross-interaction between GPR55 and CB~2~R modulates partner receptor mediated signaling. Co-expression of CB~2~R with GPR55 reduces GPR55 agonist-mediated activation of transcription factors, whereas CB2 receptor-mediated signaling was inhibited by co-expression with GPR55 ([@B6]). GPR55-CB~2~R crosstalk in neutrophils was demonstrated by the finding that GPR55 activation led to augmented neutrophil chemotaxis and reduced CB~2~R-mediated tissue injury in the site of inflammation, suggesting a possible cellular mechanism of GPR55-mediated immune cell modulation ([@B5]). Consequently, further investigations on ligand-specific signaling pathways are required to develop a specific pharmacological target for precise and designated immune modulation.

ECS in CNS Injury
-----------------

Central nervous system injury includes traumatic brain injury, stroke, cerebral aneurysms, and spinal cord injuries. Survivors from acute CNS injury often have complications due to infections. The incidence of fatal infections is linked to severity of CNS injury and the status of immune system ([@B39]; [@B73]). Following acute CNS injury, cell death occurs at the primary site and cytotoxins are released, which trigger significant secondary cell death outside the original injury area. In addition, function of the blood brain barrier is impaired, allowing systemic inflammatory mediators and cells to enter the normally protected CNS tissue, leading to the pathology of a CNS injury, i.e., neuroinflammation. The level of neuroinflammation is highly dependent on the severity, duration, and the anatomical context of the CNS injury. To prevent the excessive action of pro-inflammatory cytokines after their initial beneficial effects, the immune system releases several anti-inflammatory mediators, such as IL-10 and IL-1 receptor antagonist and soluble tumor necrosis factor receptors. This begins a cascade of compensatory anti-inflammatory response. Onset of an acute CNS injury also activates immunoinhibitory pathways, leading to a systemic brain-mediated immunosuppression to minimize secondary damage to healthy CNS tissue ([@B52]; [@B26]). Systemic immunosuppression is believed to be the main reason for infections, a leading cause of death in patients with acute CNS injury. This increased susceptibility to infections, due to impaired immune function after an acute CNS injury, has been termed "CNS injury-induced immunodeficiency syndrome" (CIDS; [@B52]).

Since the discovery of the ECS, its effects on the brain have prompted queries into its potential physiological and pathological roles. Local ECS is activated following CNS injury, representing an adaptive mechanism. The primary ligands produced in the brain are anandamide and 2-AG, which work on both CB~1~R and CB~2~R. This may play a role in modulation of CNS activity and regulation of the immune response after a CNS injury ([@B51]; [@B81]; [@B11]). There are two different directions for the potential therapeutic use of CBR: neuroprotection and immunomodulation to reduce the CNS damage and improve the outcome.

One of the potential ways the brain protects itself is by reducing its excitatory activity. It is proposed that activation of presynaptic CB~1~R reduces the release of major excitatory neurotransmitters, such as glutamate ([@B19]), which might be one of the earliest neuroprotective mechanisms deployed by the brain to prevent excitotoxicity. This is further supported by studies that showed blocking CB~1~R activity increased the vulnerability of neurons to ischemic damage and disrupted neuronal maintenance ([@B71]; [@B32]). Additionally, complete removal of the CB~1~R and associated signaling pathways causes an increase in susceptibility to ischemic damage, excitotoxin exposure, traumatic brain injury, and exacerbated inflammatory damage ([@B30]). However, early inhibition of CB~1~R activation together with increased CB~2~R activation produces beneficial effects, such as a reduction of immune cells in cerebral vasculature, a reduction in infarct size, and an improved motor function after transient focal ischemia ([@B55]; [@B24]; [@B86]; [@B1]).

The mechanism that may be related to the neuroprotective aspect of CB signaling is related to ERK in response to tissue insults and involved in cell survival mechanisms ([@B72]). ERK activation is coupled to the presence of CB~1~R in hippocampal regions ([@B48]), suggesting that CB signaling is part of the compensatory response to CNS injury. Neuronal maintenance aspects of CB signaling seem to involve MAPK. Experimental support for this notion comes from studies that showed treating the hippocampal tissue with CB~1~R antagonist AM281 blocked ERK activation through MAPK kinase and led to a compromised neuronal survival ([@B34]). On the other hand, activating the CB~1~R and promoting cell survival also showed the neuroprotective action of the ECS through ERK activity ([@B33]).

Cannabidiol, a main non-psychoactive component of cannabis, is suggested to exhibit some of its neuroprotective properties via inhibition of EC deactivation or even through its effects on vanilloid and 5-HT receptors ([@B54]; [@B3]; [@B60]). Other studies have shown that anandamide, 2-AG, THC, and synthetic agonists of CB~1~R also exhibit similar neuroprotective effects ([@B55]; [@B59]). Endogenous anandamide showed neuroprotective properties in the developing brain through CB~1~R activity ([@B82]; [@B76]). Administration of 2-AG to animals with CNS injury reduced brain edema, infarct volume, and hippocampal cell death, and improved behavioral scores, suggesting better recovery ([@B75]; [@B58]). The excitotoxic protective property of ECS activation has been reversed by administration of CB~1~R and CB~2~R antagonists, AM281 and AM630, respectively. Other CB~1~R antagonists, such as SR-141716A have been shown to reduce or completely abolish the neuroprotective properties of EC signaling in transient global cerebral ischemia ([@B55]; [@B49]). Despite piling evidence suggesting the neuroprotective role of ECS, inconsistent results and outcomes are produced. The inconsistency is due to various factors, such as the delicacy of the physiological conditions, their severity, the timing of the pathologic development of a CNS injury and the pharmacological intervention. Therefore, careful consideration needs to be given to pharmacological modulation of ECS via CBR in terms of dosage and timing of administration, otherwise the results may be counterproductive or even harmful.

Enhancing EC actions by targeting its degradation represents an alternative therapeutic approach and has shown promising results in neuroprotection. The enzyme fatty acid amide hydrolase (FAAH) is responsible for anandamide breakdown. Pharmacologic inhibition or genetic knockout of FAAH promotes neuronal maintenance and function ([@B32]; [@B16]). Block of anandamide transport with AM404 promotes CB~1~R signaling and enhances protection against excitotoxicity in hippocampal slices ([@B35]). Moreover, monoacylglycerol lipase (MAGL) hydrolyzes 2-AG to generate a major arachidonate precursor pool for neuroinflammatory prostaglandins, and is suggested as a potential drug target in neurodegenerative disease ([@B56]; [@B23]). Although there is no direct evidence suggesting the benefit of MAGL inhibition after CNS injury, we can speculate that the involved pathways could be targeted to suppress proinflammatory cascades, which arise after an acute CNS injury and contribute to exacerbated CNS damage.

Due to the changes in the immune status after an acute CNS injury and the onset of CIDS, CB~2~R expression profile on immune cells and other non-neuronal cells suggested a potential theoretical association between the detrimental effects of CNS injury and CB~2~R activity. The immune impairment could potentially be modulated through the activity of the CB~2~R, ultimately making the patient susceptible to common infections and worsening the outcome. In general, CB~2~R agonists attenuate the inflammatory response by inhibiting production of pro-inflammatory mediators, decreasing immune cell chemotaxis and reducing extravasation in the vulnerable CNS ([@B74]; [@B67]). Multiple studies have shown CB~2~R activation to be associated with neuroprotection and even improved blood brain barrier function ([@B64]). While many studies have established that the CB~2~R activation initiates immunosuppressive mechanisms and potentially limits neuroinflammation ([@B10]), others have suggested that the time-course of CB~2~R activity may hold the solution by avoiding the negative effects of neuroprotective immunosuppression, while still receiving the neuroprotective aspects of reduced neuroinflammation ([@B43]). Specifically, it is suggested that the inhibition of CB~2~R that is done too early could potentially increase the size of CNS injury, as the proinflammatory cascades and neutrophil infiltration will continue to develop. In our laboratory, we have demonstrated inhibition of CB~2~R by the selective antagonist, AM 630, significantly increased immune function as indicated by an increased leukocyte adherence to endothelia in animals challenged with LPS after hypoxia-ischemia (HI)-induced CNS injury. The CB~2~R inhibition did not affect the magnitude of infarct size in the injured brain ([@B13]). This outlines both the complexity of the CNS injury pathology, as well as the associated ECS signaling pathways, which remain to be fully explored.

Conclusion
==========

Although it has been shown that the ECS plays a vital role in the function of the immune system, controversial results exist for its regulatory role in sepsis, mainly due to the variety of methods employed to activate the receptors and the lack of truly selective ligands. In addition, *in vivo* studies using CB~2~R knockout mice showed conflicting results, which might be attributed to the complexity of the inflammatory models used in mimicking a septic state. There is a growing body of evidence for a pro-inflammatory role of GPR55 in sepsis, suggesting that selective GPR55 antagonists have a potential as a modulators of the immune response, and can be designed as a therapeutic target in sepsis.

With regards to the role of the ECS following CNS injury one may feel that cannabinoid signaling entails the "magic bullet" approach to many of the detrimental impairments associated with CNS injury. However, not all aspects of cannabinoid signaling have been fully explored and extensive pre-clinical testing is essential to find the correct ligand (or combination of ligands). Moreover, many of the studies have demonstrated a close association between ECS activity and improved functional outcome, reduced neurotoxicity, reduced infarct volume, and other beneficial effects. While this definitely suggests a bright future for this field, potential detrimental effects of ECS modulation need to be studied in more detail to prevent unwanted side effects.
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